BioCentury
ARTICLE | Clinical News

Filgotinib meets in Phase II for psoriatic arthritis

July 13, 2018 6:56 PM UTC

Gilead Sciences Inc. (NASDAQ:GILD) and Galapagos N.V. (Euronext:GLPG; NASDAQ:GLPG) said in May that once-daily 200 mg oral filgotinib (GLPG0634, GS-6034) met the primary endpoint of improving the proportion of patients with a 20% improvement in the American College of Rheumatology criteria (ACR20) at week 16 vs. placebo in the Phase II EQUATOR trial to treat moderate to severe active psoriatic arthritis (80% vs. 33%, p<0.001).

Filgotinib also met the secondary endpoints of improving ACR50 (48% vs. 15%, p<0.001) and ACR70 (23% vs. 6%, p<0.01) response rates at week 16 vs. placebo. The double-blind, European trial enrolled 131 patients...

BCIQ Target Profiles

Janus kinase-1 (JAK-1)